Loading...
XSTO
SCIB
Market cap14mUSD
Dec 05, Last price  
0.34SEK
1D
-1.75%
1Q
-3.44%
Jan 2017
-98.21%
IPO
-99.30%
Name

SciBase Holding AB (publ)

Chart & Performance

D1W1MN
XSTO:SCIB chart
P/E
—
P/S
4.68
EPS
—
Div Yield, %
—
Shrs. gr., 5y
44.93%
Rev. gr., 5y
26.21%
Revenues
30m
+27.79%
097,0001,600,0004,151,0006,436,0006,859,0006,899,0009,276,0009,521,00011,727,00017,890,00023,245,00029,705,000
Net income
-61m
L+9.97%
-40,964,393-79,502,000-38,755,000-41,532,000-53,086,000-42,464,000-44,215,000-39,539,000-34,989,000-41,690,000-39,899,000-55,585,000-61,125,000
CFO
-57m
L+10.39%
-36,437,540-34,026,000-37,077,000-46,588,000-47,850,000-44,180,000-37,482,000-37,956,000-33,861,000-39,501,000-44,466,000-51,984,000-57,383,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions in Europe and internationally. Its product includes Nevisense and Nevisense Go, a point of care platform that addresses in the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. The company has a collaboration agreement with Advanced Dermatology and Cosmetic Surgery (ADCS) group. SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.
URL
https://www.scibase.com
IPO date
Jun 02, 2015
Employees
22
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT